The US Food and Drug Administration (FDA) has approved multiple applications for first generics of Pfizer’s blockbuster drug, Lyrica (pregabalin), for treating neuropathic pain and epilepsy. The approvals were granted to Teva Pharmaceuticals, Dr. Reddy’s laboratories, Alembic Pharmaceuticals, Alkem Laboratories, Amneal Pharmaceuticals, InvaGen Pharmaceuticals, MSN Laboratories, Rising Pharmaceuticals, and Sciegen Pharmaceuticals.

Lyrica is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy, for the management of postherpetic neuralgia, as an adjunctive therapy for the treatment of partial onset seizures in patients 17 years of age and older, for the management of fibromyalgia, and for the management of neuropathic pain associated with spinal cord injury.

Source: US Food and Drug Administration